Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9

Basit Öğe Kaydı
dc.authoridGungor, Tayfun/0000-0002-7869-9662
dc.authorwosidYilmaz, Bulent/HKE-5048-2023
dc.authorwosidYilmaz, Bulent/GPK-8613-2022
dc.contributor.authorYilmaz, Bulent
dc.contributor.authorSucak, Ayhan
dc.contributor.authorKilic, Sevtap
dc.contributor.authorAksakal, Orhan
dc.contributor.authorAksoy, Yasemin
dc.contributor.authorLortlar, Nese
dc.contributor.authorSut, Necdet
dc.date.accessioned2024-06-12T11:00:24Z
dc.date.available2024-06-12T11:00:24Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractOBJECTIVE: We sought to test if metformin could regress endometriotic explants in rats. STUDY DESIGN: After inducing endometriotic implants and randomization of female Wistar albino rats, they were given 25 and 50 mg/kg/day of oral metformin in group A (n = 9) and B (n = 8), respectively, for 28 days. Group C (n = 9) was given saline as placebo. RESULTS: Mean volume, weight, and histologic score of implants in groups A (P < .01, P < .05, and P < .05, respectively) and B (P < .01, P < .05, and P < .05, respectively) were significantly lower than in group C. The activity of superoxide dismutase and tissue inhibitor of metalloproteinase-2 staining in groups A (P < .05 and P < .01, respectively) and B (P < .01 and P < .01, respectively) was significantly higher than in the control group. Moreover, there were more significant reductions in implant levels of vascular endothelial growth factor and matrix metalloproteinase-9 in groups A (both P < .001) and B (both P < .001) than in group C. CONCLUSION: Metformin causes regression of endometriotic implants in rats.en_US
dc.identifier.doi10.1016/j.ajog.2009.10.873
dc.identifier.issn0002-9378
dc.identifier.issue4en_US
dc.identifier.pmid20035912en_US
dc.identifier.scopus2-s2.0-77949913994en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.ajog.2009.10.873
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20815
dc.identifier.volume202en_US
dc.identifier.wosWOS:000276090400014en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMosby-Elsevieren_US
dc.relation.ispartofAmerican Journal Of Obstetrics And Gynecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometriosisen_US
dc.subjectMalondialdehydeen_US
dc.subjectMatrix Metalloproteinase-9en_US
dc.subjectMetforminen_US
dc.subjectRaten_US
dc.subjectSuperoxide Dismutaseen_US
dc.subjectTissue Inhibitor Of Metalloproteinase-2en_US
dc.subjectVascular Endothelial Growth Factoren_US
dc.subjectType-2 Diabetic-Patientsen_US
dc.subjectMatrix Metalloproteinasesen_US
dc.subjectEutopic Endometriumen_US
dc.subjectEstrogen-Receptoren_US
dc.subjectNude-Miceen_US
dc.subjectExpressionen_US
dc.subjectModelen_US
dc.subjectExplantsen_US
dc.subjectPeritonealen_US
dc.subjectVegfen_US
dc.titleMetformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu